BICX104 + Bupropion for Opiate Dependence

This trial tests a new method of delivering naltrexone, a medication for opioid addiction, through a small implant under the skin (BICX104 naltrexone implantable pellet). Researchers aim to determine if this implant is as effective as the existing monthly injection (Vivitrol, a naltrexone depot injection) and whether combining it with bupropion (a medication often used for depression and smoking cessation) enhances results. Ideal candidates for the trial are those who have recently been opioid-free, are generally healthy, and do not have a history of substance abuse or specific medical conditions like epilepsy or certain heart problems. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this innovative treatment.

Yes, you may need to stop certain medications. The trial excludes participants who are currently taking antidepressants, certain stimulants, or medications that could interact with the study drugs. It's best to discuss your current medications with the study team to see if they are allowed.

Research has shown that naltrexone, the main ingredient in the BICX104 implant, has been safely used to treat addiction for a long time. It is available in forms like pills and monthly injections, which patients have tolerated well. The BICX104 implant is designed to release naltrexone steadily over about three months. Previous studies on similar naltrexone implants found no major safety issues and demonstrated effectiveness in reducing opioid use.

Bupropion, also part of the trial, has been used with naltrexone in other treatments, mainly for weight loss, and has a good safety record. Some people might experience mild side effects like nausea or headaches, but these are usually not severe.

Researchers are excited about the treatments involving BICX104 and bupropion for opiate dependence because they offer innovative delivery methods and combinations. BICX104 is a naltrexone implantable pellet, which provides a long-term, consistent release of medication, potentially improving adherence compared to the standard monthly Vivitrol injections. Additionally, the combination of BICX104 with bupropion, an extended-release oral medication, could enhance effectiveness by addressing both opiate cravings and withdrawal symptoms. These approaches aim to simplify treatment regimens and improve outcomes for individuals struggling with opiate dependence.

Research has shown that naltrexone implants, such as BICX104, can aid individuals with opioid addiction by gradually releasing medication. This method has proven effective in helping people remain in treatment longer and reducing relapse risk. Studies have found that naltrexone implants can lower death rates among those addicted to opioids. In this trial, some participants will receive BICX104 alone, while others will receive BICX104 combined with bupropion. Bupropion, a medication also used for depression and smoking cessation, has shown promise in treating other addictions, such as methamphetamine addiction. While the specific combination of BICX104 and bupropion for opioid addiction is still under investigation, both have individually demonstrated effectiveness in related conditions. Additionally, another group in this trial will receive Vivitrol, a naltrexone depot injection, as a comparator.²⁶⁷⁸⁹